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ABSTRACT
Introduction: One of the most important priorities in therapy is pain control. Therefore, many different 
groups of drugs are being used for this purpose, primarily opioid analgesics and non-steroidal anti-infl am-
matory drugs (NSAIDs). Opioid analgesic tramadol, by binding to specifi c receptors, modulates the per-
ception and response to painful stimuli and inhibits transmitting and further processing of pain impulses. 
Lornoxicam, which belongs to the oxicam class of NSAIDs, is a non-selective cyclooxygenase inhibitor with 
strong analgesic and anti-infl ammatory effects, and better tolerance profi le. Preliminary research, which 
requires further verifi cation, suggests that lornoxicam may be a better alternative or adjunctive therapy 
to opioid analgesics in the treatment of moderate to severe pain. The aim of this study was to investigate 
antinociceptive effects of lornoxicam, as well as the combination of lornoxicam with tramadol.
Methods: Analgesic effect of combination of lornoxicam and tramadol or lornoxicam applied alone was 
examined on female albino mice, using a hot plate method. Measurements were made 30, 60, 90 and 
120 minutes after intraperitoneal and subcutaneous administration, in dose of 10 mg/kg.
Results: Combination of lornoxicam and tramadol, applied intraperitoneally, increases the threshold of 
sensitivity to painful stimuli, which was not the case with subcutaneous administration.
Conclusions: Lornoxicam signifi cantly increases analgesic effect when applied intraperitoneally in com-
bination with tramadol. On the other hand, lornoxicam in combination with tramadol, did not increase 
the threshold of sensitivity to painful stimuli with signifi cant difference, after subcutaneous administration.
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INTRODUCTION
Pain is defi ned by the International Association for the 
Study of Pain as „unpleasant sensory and emotional 
experience associated with actual or potential tissue 
damage“, and it is caused by nociceptive stimulus. 
Although pain is a reaction of the body to harm-
ful stimuli and is therefore a protective early warn-
ing system, the sensation of pain in postoperative 
patients has little positive eff ect. Hence, the term 
pain, derived from the Latin poena for punishment, 
refl ects the deleterious eff ects that can be infl icted 
upon the body (1). Th e goal of postoperative pain 
relief is to achieve optimal analgesia, facilitating a 
quick return to normal physiological organ function 
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with minimal side eff ects (2). Many diff erent groups 
of drugs are being used in pain control, primarily 
opioid analgesics and nonsteroidal anti-infl ammato-
ry drugs (NSAIDs).
Tramadol, a centrally acting analgesic, consists of 
two enantiomers, both of which contribute to an-
algesic activity via diff erent mechanisms. Tramadol 
is eff ective as analgesics and seems to have a better 
profi le of adverse eff ects than most opioids. Its anal-
gesic effi  cacy can further be improved by combina-
tion with a non-opioid analgesic (3-5).
Lornoxicam is a new NSAID belonging to the 
oxicam class. Compared to the other NSAIDs, 
lornoxicam demonstrates strong analgesic and an-
ti-infl ammatory eff ects, along with an improved gas-
trointestinal toxicity profi le. Its analgesic activity is 
comparable to that of opioids. High therapeutic po-
tency is indicated in low doses, with a reduced risk 
of side eff ects (6-8). Preliminary research, which re-
quires further confi rmation, suggest that lornoxicam 
may be a better alternative or adjunctive therapy to 
opioid analgesics in the treatment of moderate to 
severe pain (9, 10).
Studies have also shown that opioids may act in 
synergy with some NSAIDs, and that such combi-
nations may have therapeutic benefi t in the clinical 
treatment of infl ammatory pain (11). Th is eff ect is 
expected when combining analgesics that act at dif-
ferent areas along the route of painful stimulus, for 
example by combining nonsteroidal anti-infl amma-
tory drug (NSAID), which operates mainly in the 
periphery, and opioid, which operates centrally. Th e 
objective of development of analgesics combination 
is to achieve effi  cacy, that is, to improve therapeutic 
eff ect while using lower dosages and having less side 
eff ects. (11, 12).
Th e use of combination of oral analgesics as opposed 
to an individual therapy off ers potential benefi ts for 
the patients. Combining analgesics into a single 
product may facilitate prescribing and compliance 
by reducing the number of medicines that a patient 
must take during the pain control therapy. Combin-
ing products with diff erent mechanism of action 
may provide multimodal approach in pain therapy, 
and, in addition, enable the individual agents poten-
tially to act synergistically. Furthermore, with regard 
to safety, lower doses of each individual analgesic, 
used in combination, may result in a lower inci-
dence of individual adverse events (13).
Th e data obtained in one study indicated that the 
combination of atypical opioid tramadol and atypi-
cal NSAID propacetamol had more potent antino-
ciceptive eff ects that those of tramadol and propa-
cetamol, in mouse and rat models with acute and 
persistent pain. Study suggests that it is possible to 
increase the antinociceptive eff ects and decrease the 
undesirable side eff ects of tramadol, by coadminis-
trating propacetamol (14).
Th e fundamental concept that underlies the appro-
priate and successful management of pain by the use 
of opioid and nonopioid analgesics is individualiza-
tion of analgesic therapy (15). During the develop-
ment of multimodal analgesia, apart from increasing 
antinociception which was the primary goal, clini-
cal evaluation of combinations' benefi ts should be 
based on the benefi ts coming from reduction of ad-
verse eff ects of opioids in comparation to the side 
eff ects of non-opioids involved in such combination.
Th e aim of this study was to examine whether the 
coadministration of tramadol and lornoxicam 
change the threshold of sensitivity to painful stimuli 
and to examine the relationship between analgesia 
and method of application of the tested substances.
METHODS
Analgesic eff ects of lornoxicam in combination 
with tramadol was analysed on female albino mice, 
weighing 25-30 g. Four groups were formed, each 
consisting of ten mice. Th e sense of pain was in-
duced by thermal stimulus by the method of hot 
plate. Th e temperature of the plate was constantly 
55°C during the experiment. Analgesic eff ect was 
measured after a single intraperitoneal (i.p.) and 
subcutaneous (s.c.) administration of lornoxicam 
(in a dose of 10 mg/kg body weight), tramadol (in a 
dose of 10 mg/kg body weight) and their combina-
tion (lornoxicam and tramadol each in a dose of 10 
mg/kg body weight) in time intervals of 30, 60, 90 
and 120 minutes. Physiological solution in the same 
volume was administered to a control group.
Th e study was conducted on animal models (in vivo), 
in accordance with OECD, EPA regulation and Eu-
ropean convention for the protection of vertebrate ani-
mals used for experimental and other scientifi c purposes.
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Statistical analysis 
Statistical analysis was done using Microsoft Excel 
(Microsoft Corporation, Redmond, WA, USA) and 
SPSS for Windows (version 20.0, SPSS Inc, Chi-
cago, Illinois, USA). Th e Student’s t-test was used 
in order to determine if two sets of data are signifi -
cantly diff erent from each other 
by calculating statistically sig-
nifi cant diff erence between the 
two arithmetic means. 
Th e results are presented in the 
diagram, showing the calcu-
lated mean (average of ten mea-
surements), standard deviation 
and standard error (the ratio of 
the standard deviation and the 
square root of the number of 
measurements).
Calculated p value is based on 
a two-tailed distribution, com-
paring two sets of measure-
ments of unequal variances. 
Level of signifi cance was set at 
p<0.05.
RESULTS 
Latency period of lornoxicam 
was increased as compared to 
the control group after intra-
peritoneal administration (i.p.) 
and after subcutaneous admin-
istration (s.c.) as well. Lornoxi-
cam applied intraperitoneally 
in dose of 10 mg/kg showed 
an analgesic eff ect, statistically 
diff erent compared to the con-
trol group 60, 90 and 120 min-
utes after application (p<0.05). 
However, 30 minutes after the 
i.p. application, the latency 
period of lornoxicam was in-
creased, as compared to the con-
trol group, but with no statisti-
cally signifi cant diff erence (p = 
0.053). Subcutaneously applied 
lornoxicam showed analgesic ef-
fect compared to control group, 
in all observed time intervals 
(p<0.05).
FIGURE 2.  Comparation of analgesic effect of tested substances, after subcutane-
ous administration
FIGURE 1.  Comparation of analgesic effect of tested substances, after intraperito-
neal administration
241
http://www.jhsci.ba  Amela Saraèeviæ, Fahir Beèiæ Journal of Health Sciences 2013;3(3):238-242
Th e results have shown that lornoxicam in combi-
nation with tramadol, applied intraperitoneally, in-
crease the threshold of sensitivity to painful stimuli, 
which was not the case with subcutaneous adminis-
tration. Latency period of lornoxicam itself was 8.3, 
9.6, 9.1 and 9.4 seconds, after 30, 60, 90 and 120 
minutes respectively, after i.p. administration. On 
the other hand, latency period of lornoxicam in 
combination with tramadol was 11.6, 11.1, 12.0 
and 12.7 seconds at the same measuring points. Th e 
calculated statistical diff erence for this combination 
was signifi cant (p<0.05).
Subcutaneously administrated lornoxicam showed 
the latency period of 8.3, 9.1, 10.0 and 10.4 sec-
onds after 30, 60, 90 and 120 minutes respectively. 
Latency period of lornoxicam in combination with 
tramadol, administrated subcutaneously, was 10.1, 
10.3, 11.0 and 10.6 seconds at the same measur-
ing points. Th e calculated statistical diff erence for 
this method of application was signifi cant only 30 
minutes after application of tested combination 
(p<0.05). At later time points (60, 90 and 120 min-
utes), calculated diff erences were p=0.063, p= 0.069 
and p= 0.739, respectively.
DISCUSSION 
Studies have shown that the use of the combina-
tions of opioids and nonsteroidal anti-infl ammatory 
drugs (NSAIDs) can increase their antinociceptive 
activity and improve the therapeutic eff ect, and 
lead to the use of lower doses of opioids, resulting 
in a reduction of side eff ects. Data obtained in the 
study carried out by Zhang et al (14) indicated that 
the combination of atypical opioid, tramadol and 
atypical NSAIDs, propacetamol had more potent 
antinociceptive eff ects than those of tramadol and 
propacetamol, in mouse and rat models, in the 
treatment of acute persistent pain. If propacetamol 
is used together with tramadol clinically, the dose of 
tramadol could be minimized and then enhance the 
analgesic eff ect. Th e study suggests that it is possible 
to increase the antinociceptive eff ects and decrease 
the undesirable adverse eff ects of tramadol by coad-
ministrating propacetamol. 
Fernández - Dueñas et al. (16) investigated a syn-
ergistic interaction between fentanyl, tramadol and 
paracetamol, or whether the analgesic eff ect of this 
mixture has increased activity compared to the very 
strong opioid fentanyl, and whether it leads to a re-
duction in the dose of fentanyl, and consequently 
reduced side eff ects. Th e results showed that there is 
a synergistic interaction between these three drugs 
in reducing nociception induced by acetic acid in 
mice. Such a multimodal approach also permits 
reducing the dose of fentanyl, and reduced the in-
cidence of adverse eff ects, primarily gastrointestinal 
inhibition passage, which is a common side eff ect of 
opioid therapy.
Combinations of two analgesic drugs of the same 
or diff erent class are widely used in clinical therapy 
to enhance its antinociceptive eff ects and reduce the 
side eff ects. Moreno-Rocha et al. (17) were evaluat-
ing a possible antinociceptive synergistic interaction 
of metamizol (NSAID) and tramadol (an atypical 
opioid, opioid receptor agonist), when administered 
alone or in combination, as well as the possible devel-
opment of pharmacological tolerance produced by 
such combination. Th e results of the study showed 
that both metamizol and tramadol produced an-
tinociceptive eff ects with a low rate trend towards 
tolerance development at the end of the treatment. 
Th e antinociceptive effi  cacy of tested combination 
gradually decreased after the second injection. Th ese 
data suggested that when the combination is given 
in a unique administration it results in an impor-
tant potentiation of their individual antinociceptive 
eff ects. But, the repeated coadministration of tra-
madol and metamizol results in a development of 
tolerance.
Th e experimental part of our study presents the 
similar results. Application of individual substances 
lornoxicam and tramadol showed the expected re-
sults. Both, tramadol and lornoxicam produced a 
signifi cant analgesic eff ect in applied doses, which 
was statistically diff erent compared to the control 
group, for each method of application.
Th e combination of tramadol and lornoxicam, after 
i.p. application, produced increased pain reaction 
(enhanced antinociception) when compared to lor-
noxicam alone under the same conditions (p<0.05). 
Th ese results confi rm the literature data on combin-
ing opioids and drugs from the group of NSAIDs.
Subcutaneous administration of tested combina-
tion showed some diff erent results. Just in the fi rst 
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observed time interval after application, the com-
bination of tramadol and lornoxicam produced 
signifi cantly better analgesic eff ect compared to lor-
noxicam alone (p < 0.05). At later time points (60, 
90 and 120 minutes), the eff ect of this combination 
is almost the same as the eff ect of lornoxicam, thus, 
increased latency was demonstrated, but with no 
statistically signifi cant diff erence.
 
CONCLUSIONS 
After intraperitoneal administration, latency period 
of lornoxicam was increased as compared to the con-
trol group, with signifi cant diff erence after 60, 90 
and 120 minutes of test. Lornoxicam also showed 
increased latency when administered subcutane-
ously.
Lornoxicam signifi cantly increases analgesic eff ect 
when applied intraperitoneally in combination with 
tramadol. On the other hand, lornoxicam in combi-
nation with tramadol, did not increase the threshold 
of sensitivity to painful stimuli with signifi cant dif-
ference, after subcutaneous administration.
Th e fi ndings of the combination that includes opi-
oid and nonopioid reveal that it has potential for 
development as one of the new strategies of analge-
sics. Any clinical decision of using such multimodal 
approach in pain therapy, in addition to increasing 
the antinociception which has been experimentally 
demonstrated in our study, should also be based on 
the benefi ts coming from reduction of adverse ef-
fects of opioids in comparation to the side eff ects of 
non-opioids involved in such combination.
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